ARTICLE | Company News
Amgen, Apotex hematology news
October 5, 2015 7:00 AM UTC
A judge in the U.S. District Court for the Southern District of Florida ordered Amgen and Apotex to participate in mediation following an August lawsuit in which Amgen alleged Apotex infringed U.S. Patent Nos. 8,952,138 and 5,824,784 under the Biologics Price Competition and Innovation Act of 2009 (BPCIA) by seeking approval of a biosimilar of Amgen’s neutropenia drug Neulasta pegfilgrastim. All proceedings of the mediation will be confidential and privileged. ...